Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer

Exclusion Criteria

• •1. Patients diagnosed with other types of pancreatic cancer than adenocarcinomas (eg neuroendocrine cancer).
• •2. Advanced disease that allows primary surgical treatment.
• •3. Borderline pancreatic cancer (BRPC) disease.
• •4. The presence of metastases.
• •5. Previous systemic treatment because of pancreatic adenocarcinoma.
• •6. Preoperative radiotherapy in the abdominal area.
• •7. Previous radical surgery for pancreatic adenocarcinoma.
• •8. Large surgical procedure with the exception of diagnostic biopsies within the last 4 weeks after the start of treatment and / or patients who have not fully recovered after surgery.
• •9. Heart failure (NYHA Class II, III or IV)
• •10. Hemodynamic instability in the course of coronary and / or valvular heart disease and / or hypertension and / or other clinical conditions (eg uncontrolled diabetes mellitus).
• •11. Clinically relevant cardiac arrhythmias requiring treatment.
• •12. Stroke and / or myocardial infarction history within 6 months of inclusion.
• •13. Respiratory failure associated with other co-morbidities.
• •14. Serious psychiatric illnesses, which, in the researcher's opinion, could have a significant negative impact on the safety of the treatment.
• •15. Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.
• •16. Transplanted organ transplant including allogeneic bone marrow transplant.
• •17. Positive diagnosis for HBV or HCV indicating acute or chronic infection (for screening).
• •18. HIV infection.
• •19. The period of pregnancy and breastfeeding.
• •20. Alcoholism or drug abuse.
• •21. Limited legal capacity.